CN114667294A - 特异性结合b细胞成熟抗原的抗体及其用途 - Google Patents

特异性结合b细胞成熟抗原的抗体及其用途 Download PDF

Info

Publication number
CN114667294A
CN114667294A CN202080077674.5A CN202080077674A CN114667294A CN 114667294 A CN114667294 A CN 114667294A CN 202080077674 A CN202080077674 A CN 202080077674A CN 114667294 A CN114667294 A CN 114667294A
Authority
CN
China
Prior art keywords
car
cell
antibody
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080077674.5A
Other languages
English (en)
Other versions
CN114667294B (zh
Inventor
刘江海
曾昕
刘彬
孔洋
曾顺泽
林静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Shengshi Ruike Biotechnology Co ltd
Chengdu Shengshijunlian Biotechnology Co ltd
Original Assignee
Chengdu Shengshi Ruike Biotechnology Co ltd
Chengdu Shengshijunlian Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Shengshi Ruike Biotechnology Co ltd, Chengdu Shengshijunlian Biotechnology Co ltd filed Critical Chengdu Shengshi Ruike Biotechnology Co ltd
Publication of CN114667294A publication Critical patent/CN114667294A/zh
Application granted granted Critical
Publication of CN114667294B publication Critical patent/CN114667294B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Abstract

提供了特异性结合B细胞成熟抗原的抗体及其用途。涉及一种能特异性结合B细胞成熟抗原的抗体或其活性片段，以及包含该抗体或其活性片段的融合蛋白。融合蛋白可以包含所述抗体或其活性片段、跨膜结构域和共刺激信号传导区，所述的抗体或其活性片段能够特异性结合肿瘤特异性抗原B细胞成熟抗原，并通过跨膜结构域和共刺激信号传导区激活T细胞。还提供了能够表达该融合蛋白的CAR‑T细胞，其以B细胞成熟抗原为靶抗原，利用CAR‑T细胞特异性地杀伤肿瘤细胞，例如多发性骨髓瘤或急性髓细胞性白血病。CAR‑T可作为肿瘤类疾病的治疗药物，为肿瘤的预防和治疗提供了新的方法。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080077674.5A 2019-09-02 2020-09-02 特异性结合b细胞成熟抗原的抗体及其用途 Active CN114667294B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910822773 2019-09-02
CN2019108227730 2019-09-02
PCT/CN2020/113046 WO2021043169A1 (zh) 2019-09-02 2020-09-02 特异性结合b细胞成熟抗原的抗体及其用途

Publications (2)

Publication Number Publication Date
CN114667294A true CN114667294A (zh) 2022-06-24
CN114667294B CN114667294B (zh) 2024-04-16

Family

ID=74852441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080077674.5A Active CN114667294B (zh) 2019-09-02 2020-09-02 特异性结合b细胞成熟抗原的抗体及其用途

Country Status (2)

Country Link
CN (1) CN114667294B (zh)
WO (1) WO2021043169A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724976A (zh) * 2022-10-31 2023-03-03 北京奇迈永华生物科技有限公司 Car修饰的免疫细胞、制备方法及其应用
CN116333172A (zh) * 2023-05-04 2023-06-27 广州百暨基因科技有限公司 融合蛋白及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115703829A (zh) * 2021-08-16 2023-02-17 厦门大学 针对SARS-CoV-2的单域抗体及其用途
CN115028734A (zh) * 2022-06-29 2022-09-09 广东康盾创新产业集团股份公司 一种靶向bcma的嵌合抗原受体及其用途
CN117186229B (zh) * 2022-12-06 2024-03-29 成都赛恩吉诺生物科技有限公司 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN109153731A (zh) * 2015-08-11 2019-01-04 南京传奇生物科技有限公司 靶向bcma的嵌合抗原受体及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151817A2 (en) * 2017-02-17 2018-08-23 Unum Therapeutics Inc. Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders
US11447559B2 (en) * 2017-09-29 2022-09-20 Mogam Institute For Biomedical Research Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
CN109678961A (zh) * 2019-01-15 2019-04-26 深圳市南科生物工程有限公司 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
CN110041433B (zh) * 2019-04-26 2020-12-22 上海科棋药业科技有限公司 一种靶向bcma的嵌合抗原受体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109153731A (zh) * 2015-08-11 2019-01-04 南京传奇生物科技有限公司 靶向bcma的嵌合抗原受体及其使用方法
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724976A (zh) * 2022-10-31 2023-03-03 北京奇迈永华生物科技有限公司 Car修饰的免疫细胞、制备方法及其应用
CN115724976B (zh) * 2022-10-31 2024-03-22 北京奇迈永华生物科技有限公司 Car修饰的免疫细胞、制备方法及其应用
CN116333172A (zh) * 2023-05-04 2023-06-27 广州百暨基因科技有限公司 融合蛋白及其应用
CN116333172B (zh) * 2023-05-04 2024-02-09 广州百暨基因科技有限公司 融合蛋白及其应用

Also Published As

Publication number Publication date
CN114667294B (zh) 2024-04-16
WO2021043169A1 (zh) 2021-03-11

Similar Documents

Publication Publication Date Title
CN109134665B (zh) 一种基于单域抗体的bcma嵌合抗原受体及应用
JP7012056B2 (ja) 養子細胞療法薬を製造するための改善された方法
JP7280828B2 (ja) Ｂｃｍａを標的とする抗体およびその使用
US20190307797A1 (en) Chimeric antigen receptor and car-t cells that bind bcma
RU2744245C2 (ru) Антитело против глипикана-3 и его применение
CN114667294B (zh) 特异性结合b细胞成熟抗原的抗体及其用途
WO2021057823A1 (en) Ror1 specific chimeric antigen receptors and their therapeutic applications
CN111848809A (zh) 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
US11643468B2 (en) Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders
JP7138989B1 (ja) メソテリンに特異的に結合する抗メソテリンキメラ抗原受容体
WO2021057866A1 (zh) 一种单域抗体及包含抗体结构的嵌合抗原受体
WO2020160419A1 (en) Signaling platforms for chimeric antigen receptor t cells
US20240024475A1 (en) Antigen-Binding Protein Targeting CD70 and Use Thereof
JP2023540023A (ja) Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞
JP2023508608A (ja) 強化されたｔ細胞受容体ｓｔａｒ及びその用途
WO2023273762A1 (zh) 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115124599A (zh) 特异性结合pdl1的多肽及其用途
CN114907487A (zh) 新型嵌合抗原受体以及包含其的免疫细胞
KR20240034234A (ko) 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
WO2023139257A1 (en) Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
CN117343177A (zh) 一种驼源重链抗体或抗原结合片段及应用
EA045097B1 (ru) Химерный антигенный рецептор для bcma на основе однодоменного антитела и его применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant